Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine Rollover Study
NCT03926143Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jun 2019
- Primary completion
- May 2022
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of anetumab ravtansine in solid tumor, sponsored by Bayer. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events at 3 years. Started Jun 2019; status: terminated.
02
Drugs
anetumab ravtansine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03926143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926143.